Gene associations
This page shows the different gene sets that are used in LIDPD. External resources such as Entrez, dbSNP, or Pubmed are referenced from the table. You can find all networks for a particular gene by clicking on the respective Search link in the first column. All tables can be sorted by clicking on a particular column name.
Input contains the genes defined in the user input file, in this particular example the genes have been curated from the publication ""Genetics of Tardive Dyskinesia"" by Lee & Kang.Panel: LID contains 12 genes and 16 single nucleotide polymorphisms associated with Levodopa-induced dyskinesia that we curated from the literature. The different Highlight datasets contain additional gene annotations, e.g., associations with Parkinson's disease (PDRelated, PDCandidate, and PDGWAS contain PD associations with decreasing evidence levels), drug targets (DrugApproved), or Gene Ontology annotations (GOslimPD describes Parkinson's disease associated processes, GOslimNeuro neurotransmitter-associated processes).
Please note that while the Panel table lists all genes of the datasets, the highlight tables only show those genes that are present in at least one network, with a maximum of 200 entries. As a result, you might encounter empty highlight sets. To explore the full set you have to download the data archive. Please contact us if you think that we missed an association or if you spotted an error in the data.
Click here to search for all sets and networks involving any of the 23 genes of this set.
Click here to search for all sets and networks involving any of the 12 genes of this set.
Click here to search for all sets and networks involving any of the 170 genes of this set.
| Search | Entrez Gene ID | HGNC Symbol | UniProtKB Acc | Drugbank ID | Drug name | Known action | Actions | Type | Groups | Description |
|---|---|---|---|---|---|---|---|---|---|---|
| Search | 1312 | COMT | P21964 | DB00323 | Tolcapone | yes | inhibitor | small molecule | approved, withdrawn | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia] |
| Search | 7153 | TOP2A | P11388 | DB00380 | Dexrazoxane | yes | inhibitor | small molecule | approved, withdrawn | \\An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] |
| Search | 1813 | DRD2 | P14416 | DB00409 | Remoxipride | yes | antagonist | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 3356 | HTR2A | P28223 | DB00409 | Remoxipride | unknown | other/unknown | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 1814 | DRD3 | P35462 | DB00409 | Remoxipride | unknown | antagonist | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 1815 | DRD4 | P21917 | DB00409 | Remoxipride | unknown | antagonist | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 7153 | TOP2A | P11388 | DB00685 | Trovafloxacin | unknown | inhibitor | small molecule | approved, withdrawn | Trovafloxacin (sold as Trovan by Pfizer) is a broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was withdrawn from the market due to the risk of hepatotoxicity. It had better gram-positive bacterial coverage and less gram-negative coverage than the previous fluoroquinolones. [Wikipedia] |
| Search | 154 | ADRB2 | P07550 | DB00866 | Alprenolol | yes | antagonist | small molecule | approved, withdrawn | One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. |
| Search | 3350 | HTR1A | P08908 | DB00866 | Alprenolol | yes | antagonist | small molecule | approved, withdrawn | One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. |
| Search | 1813 | DRD2 | P14416 | DB00875 | Flupentixol | yes | antagonist | small molecule | approved, withdrawn | Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States. |
| Search | 1128 | CHRM1 | P11229 | DB00875 | Flupentixol | unknown | antagonist | small molecule | approved, withdrawn | Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States. |
| Search | 3356 | HTR2A | P28223 | DB00875 | Flupentixol | yes | antagonist | small molecule | approved, withdrawn | Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States. |
| Search | 6531 | SLC6A3 | Q01959 | DB01149 | Nefazodone | unknown | inhibitor | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 3358 | HTR2C | P28335 | DB01149 | Nefazodone | yes | antagonist | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 3350 | HTR1A | P08908 | DB01149 | Nefazodone | yes | antagonist | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 3356 | HTR2A | P28223 | DB01149 | Nefazodone | yes | antagonist | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 150 | ADRA2A | P08913 | DB01149 | Nefazodone | unknown | antagonist | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 1128 | CHRM1 | P11229 | DB01231 | Diphenidol | yes | antagonist | small molecule | approved, withdrawn | Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children. |
| Search | 1129 | CHRM2 | P08172 | DB01231 | Diphenidol | yes | antagonist | small molecule | approved, withdrawn | Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children. |
| Search | 1813 | DRD2 | P14416 | DB01239 | Chlorprothixene | yes | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1128 | CHRM1 | P11229 | DB01239 | Chlorprothixene | no | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 3358 | HTR2C | P28335 | DB01239 | Chlorprothixene | yes | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1129 | CHRM2 | P08172 | DB01239 | Chlorprothixene | no | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 3356 | HTR2A | P28223 | DB01239 | Chlorprothixene | yes | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1814 | DRD3 | P35462 | DB01239 | Chlorprothixene | yes | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1132 | CHRM4 | P08173 | DB01239 | Chlorprothixene | no | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 801 | CALM1 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 801 | CALM2 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 801 | CALM3 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 805 | CALM1 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 805 | CALM2 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 805 | CALM3 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 808 | CALM1 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 808 | CALM2 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 808 | CALM3 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 1813 | DRD2 | P14416 | DB06144 | Sertindole | yes | antagonist | small molecule | approved, withdrawn | Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market. |
| Search | 3358 | HTR2C | P28335 | DB06144 | Sertindole | yes | antagonist | small molecule | approved, withdrawn | Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market. |
| Search | 3356 | HTR2A | P28223 | DB06144 | Sertindole | yes | antagonist | small molecule | approved, withdrawn | Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market. |
| Search | 154 | ADRB2 | P07550 | DB00397 | Phenylpropanolamine | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug. |
| Search | 150 | ADRA2A | P08913 | DB00397 | Phenylpropanolamine | yes | agonist | small molecule | approved, vet_approved, withdrawn | Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug. |
| Search | 1813 | DRD2 | P14416 | DB01186 | Pergolide | yes | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3358 | HTR2C | P28335 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3352 | HTR1D | P28221 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3351 | HTR1B | P28222 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3350 | HTR1A | P08908 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3356 | HTR2A | P28223 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 1814 | DRD3 | P35462 | DB01186 | Pergolide | yes | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 1815 | DRD4 | P21917 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 150 | ADRA2A | P08913 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 151 | ADRA2B | P18089 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 152 | ADRA2C | P18825 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 5020 | OXT | P01178 | DB00107 | Oxytocin | unknown | binder | biotech | approved, vet_approved | Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity. |
| Search | 2890 | GRIA1 | P42261 | DB00228 | Enflurane | yes | antagonist | small molecule | approved, vet_approved | An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate. [PubChem] |
| Search | 1956 | EGFR | P00533 | DB00281 | Lidocaine | unknown | antagonist | small molecule | approved, vet_approved | A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem] |
| Search | 1128 | CHRM1 | P11229 | DB00366 | Doxylamine | unknown | antagonist | small molecule | approved, vet_approved | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. [PubChem] |
| Search | 1586 | CYP17A1 | P05093 | DB00396 | Progesterone | unknown | inhibitor | small molecule | approved, vet_approved | The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem] |
| Search | 4986 | OPRK1 | P41145 | DB00396 | Progesterone | unknown | activator | small molecule | approved, vet_approved | The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem] |
| Search | 2099 | ESR1 | P03372 | DB00396 | Progesterone | yes | agonist | small molecule | approved, vet_approved | The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem] |
| Search | 1813 | DRD2 | P14416 | DB00420 | Promazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1128 | CHRM1 | P11229 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 3358 | HTR2C | P28335 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1129 | CHRM2 | P08172 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 3356 | HTR2A | P28223 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1815 | DRD4 | P21917 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1132 | CHRM4 | P08173 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1813 | DRD2 | P14416 | DB00433 | Prochlorperazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) |
| Search | 1813 | DRD2 | P14416 | DB00450 | Droperidol | yes | antagonist | small molecule | approved, vet_approved | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) |
| Search | 1813 | DRD2 | P14416 | DB00477 | Chlorpromazine | yes | antagonist | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 1128 | CHRM1 | P11229 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 3358 | HTR2C | P28335 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 3350 | HTR1A | P08908 | DB00477 | Chlorpromazine | yes | antagonist | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 3356 | HTR2A | P28223 | DB00477 | Chlorpromazine | yes | antagonist | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 1814 | DRD3 | P35462 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 1815 | DRD4 | P21917 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 59340 | HRH4 | Q9H3N8 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 801 | CALM1 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 801 | CALM2 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 801 | CALM3 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 805 | CALM1 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 805 | CALM2 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 805 | CALM3 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 808 | CALM1 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 808 | CALM2 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 808 | CALM3 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 1813 | DRD2 | P14416 | DB00508 | Triflupromazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem] |
| Search | 1128 | CHRM1 | P11229 | DB00508 | Triflupromazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem] |
| Search | 1129 | CHRM2 | P08172 | DB00508 | Triflupromazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem] |
| Search | 7846 | TUBA1A | Q71U36 | DB00518 | Albendazole | no | inhibitor | small molecule | approved, vet_approved | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) |
| Search | 801 | CALM1 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 801 | CALM2 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 801 | CALM3 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 805 | CALM1 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 805 | CALM2 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 805 | CALM3 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 808 | CALM1 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 808 | CALM2 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 808 | CALM3 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 1128 | CHRM1 | P11229 | DB00572 | Atropine | yes | antagonist | small molecule | approved, vet_approved | An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae. [PubChem] |
| Search | 1129 | CHRM2 | P08172 | DB00572 | Atropine | yes | antagonist | small molecule | approved, vet_approved | An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae. [PubChem] |
| Search | 1132 | CHRM4 | P08173 | DB00572 | Atropine | yes | antagonist | small molecule | approved, vet_approved | An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae. [PubChem] |
| Search | 2 | A2M | P01023 | DB00626 | Bacitracin | unknown | inhibitor | small molecule | approved, vet_approved | \\Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically. |
| Search | 150 | ADRA2A | P08913 | DB00633 | Dexmedetomidine | yes | agonist | small molecule | approved, vet_approved | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem] |
| Search | 3290 | HSD11B1 | P28845 | DB00635 | Prednisone | unknown | ligand | small molecule | approved, vet_approved | A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem] |
| Search | 7846 | TUBA1A | Q71U36 | DB00643 | Mebendazole | yes | inhibitor | small molecule | approved, vet_approved | A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem] |
| Search | 4988 | OPRM1 | P35372 | DB00652 | Pentazocine | yes | antagonist | small molecule | approved, vet_approved | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) |
| Search | 4986 | OPRK1 | P41145 | DB00652 | Pentazocine | yes | agonist | small molecule | approved, vet_approved | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) |
| Search | 154 | ADRB2 | P07550 | DB00668 | Epinephrine | yes | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB00668 | Epinephrine | yes | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 151 | ADRA2B | P18089 | DB00668 | Epinephrine | yes | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 152 | ADRA2C | P18825 | DB00668 | Epinephrine | unknown | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 2890 | GRIA1 | P42261 | DB00753 | Isoflurane | yes | antagonist | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 801 | CALM1 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 801 | CALM2 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 801 | CALM3 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 805 | CALM1 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 805 | CALM2 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 805 | CALM3 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 808 | CALM1 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 808 | CALM2 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 808 | CALM3 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB00797 | Tolazoline | unknown | antagonist | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 151 | ADRA2B | P18089 | DB00797 | Tolazoline | unknown | binder | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 152 | ADRA2C | P18825 | DB00797 | Tolazoline | unknown | binder | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 3309 | HSPA5 | P11021 | DB00945 | Acetylsalicylic acid | unknown | binding | small molecule | approved, vet_approved | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) |
| Search | 1909 | EDNRA | P25101 | DB00945 | Acetylsalicylic acid | unknown | small molecule | approved, vet_approved | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) | |
| Search | 7157 | TP53 | P04637 | DB00945 | Acetylsalicylic acid | unknown | acetylation | small molecule | approved, vet_approved | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) |
| Search | 6197 | RPS6KA3 | P51812 | DB00945 | Acetylsalicylic acid | unknown | small molecule | approved, vet_approved | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) | |
| Search | 154 | ADRB2 | P07550 | DB01001 | Salbutamol | yes | agonist | small molecule | approved, vet_approved | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma. |
| Search | 2890 | GRIA1 | P42261 | DB01028 | Methoxyflurane | yes | antagonist | small molecule | approved, vet_approved | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) |
| Search | 5770 | PTPN1 | P18031 | DB01133 | Tiludronate | unknown | inhibitor | small molecule | approved, vet_approved | Tiludronate is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates. |
| Search | 3760 | KCNJ3 | P48549 | DB01159 | Halothane | unknown | inhibitor | small molecule | approved, vet_approved | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) |
| Search | 3763 | KCNJ6 | P48051 | DB01159 | Halothane | unknown | inhibitor | small molecule | approved, vet_approved | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) |
| Search | 54331 | GNG2 | P59768 | DB01159 | Halothane | unknown | other/unknown | small molecule | approved, vet_approved | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) |
| Search | 1385 | CREB1 | P16220 | DB01183 | Naloxone | no | other/unknown | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 4988 | OPRM1 | P35372 | DB01183 | Naloxone | yes | antagonist | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 4986 | OPRK1 | P41145 | DB01183 | Naloxone | yes | antagonist | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 4985 | OPRD1 | P41143 | DB01183 | Naloxone | yes | antagonist | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 2099 | ESR1 | P03372 | DB01183 | Naloxone | no | antagonist|other/unknown | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 124 | ADH1A | P07327 | DB01213 | Fomepizole | yes | inhibitor | small molecule | approved, vet_approved | Fomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites. |
| Search | 125 | ADH1B | P00325 | DB01213 | Fomepizole | yes | inhibitor | small molecule | approved, vet_approved | Fomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites. |
| Search | 1813 | DRD2 | P14416 | DB01221 | Ketamine | unknown | agonist|partial agonist | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 4988 | OPRM1 | P35372 | DB01221 | Ketamine | unknown | binder | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 4986 | OPRK1 | P41145 | DB01221 | Ketamine | unknown | agonist | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 4985 | OPRD1 | P41143 | DB01221 | Ketamine | unknown | binder | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 81027 | TUBB1 | Q9H4B7 | DB01229 | Paclitaxel | yes | inhibitor | small molecule | approved, vet_approved | \\Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. |
| Search | 4137 | MAPT | P10636 | DB01229 | Paclitaxel | yes | small molecule | approved, vet_approved | \\Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. | |
| Search | 2890 | GRIA1 | P42261 | DB01236 | Sevoflurane | yes | antagonist | small molecule | approved, vet_approved | Sevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia] |
| Search | 2950 | GSTP1 | P09211 | DB01242 | Clomipramine | unknown | inhibitor | small molecule | approved, vet_approved | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, TouretteÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. |
| Search | 3358 | HTR2C | P28335 | DB01242 | Clomipramine | yes | antagonist | small molecule | approved, vet_approved | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, TouretteÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. |
| Search | 3356 | HTR2A | P28223 | DB01242 | Clomipramine | yes | antagonist | small molecule | approved, vet_approved | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, TouretteÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. |
| Search | 1392 | CRH | P06850 | DB01285 | Corticotropin | unknown | agonist | biotech | approved, vet_approved | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. |
| Search | 1813 | DRD2 | P14416 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3358 | HTR2C | P28335 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3352 | HTR1D | P28221 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3351 | HTR1B | P28222 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3350 | HTR1A | P08908 | DB01392 | Yohimbine | unknown | partial agonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3356 | HTR2A | P28223 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 1814 | DRD3 | P35462 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB01392 | Yohimbine | yes | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 151 | ADRA2B | P18089 | DB01392 | Yohimbine | yes | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 152 | ADRA2C | P18825 | DB01392 | Yohimbine | yes | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 154 | ADRB2 | P07550 | DB01407 | Clenbuterol | yes | agonist | small molecule | approved, vet_approved | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem] |
| Search | 4803 | NGF | P01138 | DB01407 | Clenbuterol | unknown | stimulator | small molecule | approved, vet_approved | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem] |
| Search | 367 | AR | P10275 | DB01420 | Testosterone Propionate | yes | agonist | small molecule | approved, vet_approved | An ester of testosterone with a propionate substitution at the 17-beta position. [PubChem] |
| Search | 1813 | DRD2 | P14416 | DB01614 | Acepromazine | yes | antagonist | small molecule | approved, vet_approved | Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. |
| Search | 3350 | HTR1A | P08908 | DB01614 | Acepromazine | yes | antagonist | small molecule | approved, vet_approved | Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. |
| Search | 3356 | HTR2A | P28223 | DB01614 | Acepromazine | yes | antagonist | small molecule | approved, vet_approved | Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. |
| Search | 1132 | CHRM4 | P08173 | DB01625 | Isopropamide | unknown | antagonist | small molecule | approved, vet_approved | Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility. |
| Search | 2099 | ESR1 | P03372 | DB04573 | Estriol | yes | agonist | small molecule | approved, vet_approved | A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes. |
| Search | 2100 | ESR2 | Q92731 | DB04573 | Estriol | unknown | agonist | small molecule | approved, vet_approved | A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes. |
| Search | 4128 | MAOA | P21397 | DB01363 | Ephedra | yes | inhibitor | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 6531 | SLC6A3 | Q01959 | DB01363 | Ephedra | yes | negative modulator | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 4129 | MAOB | P27338 | DB01363 | Ephedra | yes | inhibitor | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 154 | ADRB2 | P07550 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 150 | ADRA2A | P08913 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 151 | ADRA2B | P18089 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 152 | ADRA2C | P18825 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 645 | BLVRB | P30043 | DB00140 | Riboflavin | yes | product of | small molecule | approved, nutraceutical, vet_approved | Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. [PubChem] |
| Search | 2841 | GPR18 | Q14330 | DB00145 | Glycine | unknown | small molecule | approved, nutraceutical, vet_approved | A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem] | |
| Search | 216 | ALDH1A1 | P00352 | DB00162 | Vitamin A | unknown | small molecule | approved, nutraceutical, vet_approved | Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of carotenoids found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products. [PubChem] | |
| Search | 220 | ALDH1A3 | P47895 | DB00162 | Vitamin A | unknown | small molecule | approved, nutraceutical, vet_approved | Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of carotenoids found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products. [PubChem] | |
| Search | 2099 | ESR1 | P03372 | DB01065 | Melatonin | unknown | antagonist | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. |
| Search | 801 | CALM1 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 801 | CALM2 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 801 | CALM3 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 805 | CALM1 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 805 | CALM2 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 805 | CALM3 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 808 | CALM1 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 808 | CALM2 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 808 | CALM3 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 4543 | MTNR1A | P48039 | DB01065 | Melatonin | yes | agonist | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. |
| Search | 4544 | MTNR1B | P49286 | DB01065 | Melatonin | yes | agonist | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. |
| Search | 1312 | COMT | P21964 | DB00118 | S-Adenosylmethionine | unknown | cofactor | small molecule | approved, nutraceutical | Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) |
| Search | 2193 | FARSA | Q9Y285 | DB00120 | L-Phenylalanine | unknown | small molecule | approved, nutraceutical | An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem] | |
| Search | 4846 | NOS3 | P29474 | DB00125 | L-Arginine | unknown | small molecule | approved, nutraceutical | An essential amino acid that is physiologically active in the L-form. [PubChem] | |
| Search | 1621 | DBH | P09172 | DB00126 | Vitamin C | unknown | small molecule | approved, nutraceutical | A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. [PubChem] | |
| Search | 4069 | LYZ | P61626 | DB00128 | L-Aspartic Acid | unknown | small molecule | approved, nutraceutical | One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. [PubChem] | |
| Search | 1385 | CREB1 | P16220 | DB00131 | Adenosine monophosphate | unknown | activator | small molecule | approved, nutraceutical | Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem] |
| Search | 107 | ADCY1 | Q08828 | DB00131 | Adenosine monophosphate | unknown | product of | small molecule | approved, nutraceutical | Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem] |
Click here to search for all sets and networks involving any of the 57 genes of this set.
| Search | Entrez Gene ID | HGNC Approved Symbol | UniProtKB Acc | Human Ensembl Gene ID | Panel GO term ID | Panel GO term name | GO term ID | GO term name |
|---|---|---|---|---|---|---|---|---|
| Search | 2778 | GNAS | O95467 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 101927137 | ATP1A3 | P13637 | ENSG00000105409 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 101927137 | CCT3 | P13637 | ENSG00000105409 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 101927137 | FAM78A | P13637 | ENSG00000105409 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 101927137 | KIAA1456 | P13637 | ENSG00000105409 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 101927137 | RN7SL784P | P13637 | ENSG00000105409 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 101927137 | SCLT1 | P13637 | ENSG00000105409 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 409 | ARRB2 | P32121 | ENSG00000141480 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | P63092 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 1742 | DLG4 | P78352 | ENSG00000132535 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | P84996 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 5781 | PTPN11 | Q06124 | ENSG00000179295 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | Q5JWF2 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 54102 | CLIC6 | Q96NY7 | ENSG00000159212 | GO:0050780 | dopamine receptor binding | GO:0050780 | dopamine receptor binding |
| Search | 2778 | GNAS | O95467 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 111 | ADCY5 | O95622 | ENSG00000173175 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 4988 | OPRM1 | P35372 | ENSG00000112038 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 54331 | GNG2 | P59768 | ENSG00000186469 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2782 | GNB1 | P62873 | ENSG00000078369 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2778 | GNAS | P63092 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2778 | GNAS | P84996 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2778 | GNAS | Q5JWF2 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 111 | ADCY5 | O95622 | ENSG00000173175 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 2316 | FLNA | P21333 | ENSG00000196924 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 2316 | FLNA | P21333 | ENSG00000269329 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 112 | ADCY6 | O43306 | ENSG00000174233 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 8787 | RGS9 | O75916 | ENSG00000108370 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 2775 | GNAO1 | P09471 | ENSG00000087258 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 9630 | GNA14 | O95837 | ENSG00000156049 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 2767 | GNA11 | P29992 | ENSG00000088256 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 2769 | GNA15 | P30679 | ENSG00000060558 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 2776 | GNAQ | P50148 | ENSG00000156052 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007212 | dopamine receptor signaling pathway | GO:0060159 | regulation of dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0060160 | negative regulation of dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0060160 | negative regulation of dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0060161 | positive regulation of dopamine receptor signaling pathway |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007212 | dopamine receptor signaling pathway | GO:0060161 | positive regulation of dopamine receptor signaling pathway |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0005329 | dopamine transmembrane transporter activity | GO:0005329 | dopamine transmembrane transporter activity |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0005329 | dopamine transmembrane transporter activity | GO:0005330 | dopamine:sodium symporter activity |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1392 | CRH | P06850 | ENSG00000147571 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 409 | ARRB2 | P32121 | ENSG00000141480 | GO:0001963 | synaptic transmission, dopaminergic | GO:0032226 | positive regulation of synaptic transmission, dopaminergic |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051585 | negative regulation of dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 1855 | DVL1 | O14640 | ENSG00000107404 | GO:0001505 | regulation of neurotransmitter levels | GO:0001505 | regulation of neurotransmitter levels |
| Search | 11255 | HRH3 | Q9Y5N1 | ENSG00000101180 | GO:0001505 | regulation of neurotransmitter levels | GO:0001505 | regulation of neurotransmitter levels |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0001956 | positive regulation of neurotransmitter secretion |
| Search | 2852 | GPER1 | Q99527 | ENSG00000164850 | GO:0001505 | regulation of neurotransmitter levels | GO:0001956 | positive regulation of neurotransmitter secretion |
| Search | 1855 | DVL1 | O14640 | ENSG00000107404 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 3312 | HSPA8 | P11142 | ENSG00000109971 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 85389 | HSPA8 | P11142 | ENSG00000109971 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 85389 | SNORD14C | P11142 | ENSG00000109971 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 85390 | HSPA8 | P11142 | ENSG00000109971 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 85390 | SNORD14D | P11142 | ENSG00000109971 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 4128 | MAOA | P21397 | ENSG00000189221 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 2914 | GRM4 | Q14833 | ENSG00000124493 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 11255 | HRH3 | Q9Y5N1 | ENSG00000101180 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 5663 | PSEN1 | P49768 | ENSG00000080815 | GO:0001505 | regulation of neurotransmitter levels | GO:0016080 | synaptic vesicle targeting |
| Search | 4128 | MAOA | P21397 | ENSG00000189221 | GO:0001505 | regulation of neurotransmitter levels | GO:0042135 | neurotransmitter catabolic process |
| Search | 1312 | COMT | P21964 | ENSG00000093010 | GO:0001505 | regulation of neurotransmitter levels | GO:0042135 | neurotransmitter catabolic process |
| Search | 4128 | MAOA | P21397 | ENSG00000189221 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 1312 | COMT | P21964 | ENSG00000093010 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 223 | ALDH9A1 | P49189 | ENSG00000143149 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 4803 | NGF | P01138 | ENSG00000134259 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 815 | CAMK2A | Q9UQM7 | ENSG00000070808 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:0051582 | positive regulation of neurotransmitter uptake |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001505 | regulation of neurotransmitter levels | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0001505 | regulation of neurotransmitter levels | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051585 | negative regulation of dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001505 | regulation of neurotransmitter levels | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001505 | regulation of neurotransmitter levels | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051612 | negative regulation of serotonin uptake |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051622 | negative regulation of norepinephrine uptake |
| Search | 488 | ATP2A2 | P16615 | ENSG00000174437 | GO:0001505 | regulation of neurotransmitter levels | GO:1903233 | regulation of calcium ion-dependent exocytosis of neurotransmitter |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:1904049 | negative regulation of spontaneous neurotransmitter secretion |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0001505 | regulation of neurotransmitter levels | GO:2000300 | regulation of synaptic vesicle exocytosis |
| Search | 5906 | RAP1A | P62834 | ENSG00000116473 | GO:0001505 | regulation of neurotransmitter levels | GO:2000301 | negative regulation of synaptic vesicle exocytosis |
| Search | 10636 | RGS14 | O43566 | ENSG00000169220 | GO:0048167 | regulation of synaptic plasticity | GO:0031914 | negative regulation of synaptic plasticity |
| Search | 10755 | GIPC1 | O14908 | ENSG00000123159 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 134 | ADORA1 | P30542 | ENSG00000163485 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 5663 | PSEN1 | P49768 | ENSG00000080815 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 491 | ATP2B2 | Q01814 | ENSG00000157087 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 348 | APOE | P02649 | ENSG00000130203 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 1627 | DBN1 | Q16643 | ENSG00000113758 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 815 | CAMK2A | Q9UQM7 | ENSG00000070808 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 183 | AGT | P01019 | ENSG00000135744 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 2915 | GRM5 | P41594 | ENSG00000168959 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 1742 | DLG4 | P78352 | ENSG00000132535 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity |
| Search | 2915 | GRM5 | P41594 | ENSG00000168959 | GO:0048167 | regulation of synaptic plasticity | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048172 | regulation of short-term neuronal synaptic plasticity |
| Search | 10636 | RGS14 | O43566 | ENSG00000169220 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 1392 | CRH | P06850 | ENSG00000147571 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 5764 | PTN | P21246 | ENSG00000105894 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 5594 | MAPK1 | P28482 | ENSG00000100030 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 5590 | PRKCZ | Q05513 | ENSG00000067606 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 4915 | NTRK2 | Q16620 | ENSG00000148053 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 2890 | GRIA1 | P42261 | ENSG00000155511 | GO:0048167 | regulation of synaptic plasticity | GO:0060292 | long term synaptic depression |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0048167 | regulation of synaptic plasticity | GO:1900273 | positive regulation of long-term synaptic potentiation |
| Search | 134 | ADORA1 | P30542 | ENSG00000163485 | GO:0048167 | regulation of synaptic plasticity | GO:1900453 | negative regulation of long term synaptic depression |
Click here to search for all sets and networks involving any of the 132 genes of this set.
| Search | Entrez Gene ID | HGNC Approved Symbol | UniProtKB Acc | Human Ensembl Gene ID | Panel GO term ID | Panel GO term name | GO term ID | GO term name |
|---|---|---|---|---|---|---|---|---|
| Search | 4436 | MSH2 | P43246 | ENSG00000095002 | GO:0006119 | oxidative phosphorylation | GO:0006119 | oxidative phosphorylation |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0006119 | oxidative phosphorylation | GO:0006120 | mitochondrial electron transport, NADH to ubiquinone |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0006119 | oxidative phosphorylation | GO:0042775 | mitochondrial ATP synthesis coupled electron transport |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0006119 | oxidative phosphorylation | GO:1902957 | negative regulation of mitochondrial electron transport, NADH to ubiquinone |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0006119 | oxidative phosphorylation | GO:1902958 | positive regulation of mitochondrial electron transport, NADH to ubiquinone |
| Search | 7415 | VCP | P55072 | ENSG00000165280 | GO:0006119 | oxidative phosphorylation | GO:1903862 | positive regulation of oxidative phosphorylation |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0000422 | mitochondrion degradation | GO:0000422 | mitophagy |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0000422 | mitochondrion degradation | GO:0000422 | mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5539 | PPY | P01298 | ENSG00000108849 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 154 | ADRB2 | P07550 | ENSG00000169252 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 11140 | CDC37 | Q16543 | ENSG00000105401 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 27198 | HCAR1 | Q9BXC0 | ENSG00000196917 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0000422 | mitochondrion degradation | GO:1901525 | negative regulation of macromitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0000422 | mitochondrion degradation | GO:1903146 | regulation of mitophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0000422 | mitochondrion degradation | GO:1903147 | negative regulation of mitophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0000422 | mitochondrion degradation | GO:1903599 | positive regulation of mitophagy |
| Search | 10000 | AKT3 | Q9Y243 | ENSG00000117020 | GO:0007005 | mitochondrion organization | GO:0000002 | mitochondrial genome maintenance |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0000266 | mitochondrial fission |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0000266 | mitochondrial fission |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0000422 | mitophagy |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0000422 | mitophagy |
| Search | 6648 | SOD2 | P04179 | ENSG00000112096 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 3725 | JUN | P05412 | ENSG00000177606 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 2810 | SFN | P31947 | ENSG00000175793 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 293 | SLC25A6 | P12236 | ENSG00000169100 | GO:0007005 | mitochondrion organization | GO:0006626 | protein targeting to mitochondrion |
| Search | 3313 | HSPA9 | P38646 | ENSG00000113013 | GO:0007005 | mitochondrion organization | GO:0006626 | protein targeting to mitochondrion |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0006626 | protein targeting to mitochondrion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 506 | ATP5B | P06576 | ENSG00000110955 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 142 | PARP1 | P09874 | ENSG00000143799 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 4846 | NOS3 | P29474 | ENSG00000164867 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 10935 | PRDX3 | P30048 | ENSG00000165672 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 5245 | PHB | P35232 | ENSG00000167085 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 1432 | MAPK14 | Q16539 | ENSG00000112062 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 10891 | PPARGC1A | Q9UBK2 | ENSG00000109819 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0007005 | mitochondrion organization | GO:0007006 | mitochondrial membrane organization |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0008053 | mitochondrial fusion |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0007005 | mitochondrion organization | GO:0008637 | apoptotic mitochondrial changes |
| Search | 4214 | MAP3K1 | Q13233 | ENSG00000095015 | GO:0007005 | mitochondrion organization | GO:0008637 | apoptotic mitochondrial changes |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0010636 | positive regulation of mitochondrial fusion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0010637 | negative regulation of mitochondrial fusion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0010821 | regulation of mitochondrion organization |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0010821 | regulation of mitochondrion organization |
| Search | 10891 | PPARGC1A | Q9UBK2 | ENSG00000109819 | GO:0007005 | mitochondrion organization | GO:0010822 | positive regulation of mitochondrion organization |
| Search | 142 | PARP1 | P09874 | ENSG00000143799 | GO:0007005 | mitochondrion organization | GO:0032042 | mitochondrial DNA metabolic process |
| Search | 55037 | PTCD3 | Q96EY7 | ENSG00000132300 | GO:0007005 | mitochondrion organization | GO:0032543 | mitochondrial translation |
| Search | 9131 | AIFM1 | O95831 | ENSG00000156709 | GO:0007005 | mitochondrion organization | GO:0032981 | mitochondrial respiratory chain complex I assembly |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0035794 | positive regulation of mitochondrial membrane permeability |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0043504 | mitochondrial DNA repair |
| Search | 142 | PARP1 | P09874 | ENSG00000143799 | GO:0007005 | mitochondrion organization | GO:0043504 | mitochondrial DNA repair |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0043653 | mitochondrial fragmentation involved in apoptotic process |
| Search | 3320 | HSP90AA1 | P07900 | ENSG00000080824 | GO:0007005 | mitochondrion organization | GO:0045040 | protein import into mitochondrial outer membrane |
| Search | 3308 | HSPA4 | P34932 | ENSG00000170606 | GO:0007005 | mitochondrion organization | GO:0045040 | protein import into mitochondrial outer membrane |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 1267 | CNP | P09543 | ENSG00000173786 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 1267 | CNP | P09543 | ENSG00000260283 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:0048312 | intracellular distribution of mitochondria |
| Search | 55037 | PTCD3 | Q96EY7 | ENSG00000132300 | GO:0007005 | mitochondrion organization | GO:0070124 | mitochondrial translational initiation |
| Search | 55037 | PTCD3 | Q96EY7 | ENSG00000132300 | GO:0007005 | mitochondrion organization | GO:0070125 | mitochondrial translational elongation |
| Search | 55037 | PTCD3 | Q96EY7 | ENSG00000132300 | GO:0007005 | mitochondrion organization | GO:0070126 | mitochondrial translational termination |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0070584 | mitochondrion morphogenesis |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:0090140 | regulation of mitochondrial fission |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0090141 | positive regulation of mitochondrial fission |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0007005 | mitochondrion organization | GO:0090141 | positive regulation of mitochondrial fission |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0090200 | positive regulation of release of cytochrome c from mitochondria |
| Search | 2852 | GPER1 | Q99527 | ENSG00000164850 | GO:0007005 | mitochondrion organization | GO:0090200 | positive regulation of release of cytochrome c from mitochondria |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 551 | AVP | P01185 | ENSG00000101200 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 3479 | IGF1 | P05019 | ENSG00000017427 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 2876 | GPX1 | P07203 | ENSG00000233276 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 409 | ARRB2 | P32121 | ENSG00000141480 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5539 | PPY | P01298 | ENSG00000108849 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 154 | ADRB2 | P07550 | ENSG00000169252 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 11140 | CDC37 | Q16543 | ENSG00000105401 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 27198 | HCAR1 | Q9BXC0 | ENSG00000196917 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 10971 | YWHAQ | P27348 | ENSG00000134308 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 2810 | SFN | P31947 | ENSG00000175793 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 5599 | MAPK8 | P45983 | ENSG00000107643 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 7534 | YWHAZ | P63104 | ENSG00000164924 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 1869 | E2F1 | Q01094 | ENSG00000101412 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 292 | SLC25A5 | P05141 | ENSG00000005022 | GO:0007005 | mitochondrion organization | GO:1901029 | negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
| Search | 2932 | GSK3B | P49841 | ENSG00000082701 | GO:0007005 | mitochondrion organization | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:1901525 | negative regulation of macromitophagy |
| Search | 10891 | PPARGC1A | Q9UBK2 | ENSG00000109819 | GO:0007005 | mitochondrion organization | GO:1901860 | positive regulation of mitochondrial DNA metabolic process |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process |
| Search | 815 | CAMK2A | Q9UQM7 | ENSG00000070808 | GO:0007005 | mitochondrion organization | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process |
| Search | 1386 | ATF2 | P15336 | ENSG00000115966 | GO:0007005 | mitochondrion organization | GO:1902110 | positive regulation of mitochondrial membrane permeability involved in apoptotic process |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:1903146 | regulation of mitophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0007005 | mitochondrion organization | GO:1903147 | negative regulation of mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:1903214 | regulation of protein targeting to mitochondrion |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:1903215 | negative regulation of protein targeting to mitochondrion |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:1903217 | negative regulation of protein processing involved in protein targeting to mitochondrion |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0007005 | mitochondrion organization | GO:1903599 | positive regulation of mitophagy |
| Search | 3176 | HNMT | P50135 | ENSG00000150540 | GO:0007005 | mitochondrion organization | GO:1903955 | positive regulation of protein targeting to mitochondrion |
| Search | 10316 | NMUR1 | Q9HB89 | ENSG00000171596 | GO:0007005 | mitochondrion organization | GO:1903955 | positive regulation of protein targeting to mitochondrion |
| Search | 5663 | PSEN1 | P49768 | ENSG00000080815 | GO:0006914 | autophagy | GO:0000045 | autophagosome assembly |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0000422 | mitophagy |
| Search | 51024 | FIS1 | Q9Y3D6 | ENSG00000214253 | GO:0006914 | autophagy | GO:0000422 | mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 5663 | PSEN1 | P49768 | ENSG00000080815 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 10287 | RGS19 | P49795 | ENSG00000171700 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 2308 | FOXO1 | Q12778 | ENSG00000150907 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 6794 | STK11 | Q15831 | ENSG00000118046 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 4137 | MAPT | P10636 | ENSG00000186868 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0006914 | autophagy | GO:0010507 | negative regulation of autophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:0010507 | negative regulation of autophagy |
| Search | 2308 | FOXO1 | Q12778 | ENSG00000150907 | GO:0006914 | autophagy | GO:0010508 | positive regulation of autophagy |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0006914 | autophagy | GO:0010508 | positive regulation of autophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 23411 | SIRT1 | Q96EB6 | ENSG00000096717 | GO:0006914 | autophagy | GO:0016239 | positive regulation of macroautophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:0016242 | negative regulation of macroautophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5539 | PPY | P01298 | ENSG00000108849 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 154 | ADRB2 | P07550 | ENSG00000169252 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 11140 | CDC37 | Q16543 | ENSG00000105401 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 27198 | HCAR1 | Q9BXC0 | ENSG00000196917 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0006914 | autophagy | GO:1901525 | negative regulation of macromitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:1903146 | regulation of mitophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:1903147 | negative regulation of mitophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0006914 | autophagy | GO:1903599 | positive regulation of mitophagy |
| Search | 9531 | BAG3 | O95817 | ENSG00000151929 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 5034 | P4HB | P07237 | ENSG00000185624 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3320 | HSP90AA1 | P07900 | ENSG00000080824 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3326 | HSP90AB1 | P08238 | ENSG00000096384 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3329 | HSPD1 | P10809 | ENSG00000144381 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3312 | HSPA8 | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 85389 | HSPA8 | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 85389 | SNORD14C | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 85390 | HSPA8 | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 85390 | SNORD14D | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 100500842 | HSP90B1 | P14625 | ENSG00000166598 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 100500842 | MIR3652 | P14625 | ENSG00000166598 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 7184 | HSP90B1 | P14625 | ENSG00000166598 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 821 | CANX | P27824 | ENSG00000127022 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3301 | DNAJA1 | P31689 | ENSG00000086061 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3313 | HSPA9 | P38646 | ENSG00000113013 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 101927137 | ATP1A3 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 101927137 | CCT3 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 101927137 | FAM78A | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 101927137 | KIAA1456 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 101927137 | RN7SL784P | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 101927137 | SCLT1 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 7203 | CCT3 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 60 | ACTB | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 60 | ACTG1 | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 10376 | TUBA1B | P68363 | ENSG00000123416 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 9360 | PPIG | Q13427 | ENSG00000138398 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 10381 | TUBB3 | Q13509 | ENSG00000258947 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 10130 | PDIA6 | Q15084 | ENSG00000143870 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 11140 | CDC37 | Q16543 | ENSG00000105401 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 7846 | TUBA1A | Q71U36 | ENSG00000167552 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 84790 | TUBA1C | Q9BQE3 | ENSG00000167553 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 84617 | TUBB6 | Q9BUF5 | ENSG00000176014 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 81027 | TUBB1 | Q9H4B7 | ENSG00000101162 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 10856 | RUVBL2 | Q9Y230 | ENSG00000183207 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3329 | HSPD1 | P10809 | ENSG00000144381 | GO:0006457 | protein folding | GO:0006458 | 'de novo' protein folding |
| Search | 3309 | HSPA5 | P11021 | ENSG00000044574 | GO:0006457 | protein folding | GO:0034975 | protein folding in endoplasmic reticulum |
| Search | 100500842 | HSP90B1 | P14625 | ENSG00000166598 | GO:0006457 | protein folding | GO:0034975 | protein folding in endoplasmic reticulum |
| Search | 100500842 | MIR3652 | P14625 | ENSG00000166598 | GO:0006457 | protein folding | GO:0034975 | protein folding in endoplasmic reticulum |
| Search | 7184 | HSP90B1 | P14625 | ENSG00000166598 | GO:0006457 | protein folding | GO:0034975 | protein folding in endoplasmic reticulum |
| Search | 821 | CANX | P27824 | ENSG00000127022 | GO:0006457 | protein folding | GO:0034975 | protein folding in endoplasmic reticulum |
| Search | 3320 | HSP90AA1 | P07900 | ENSG00000080824 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 3329 | HSPD1 | P10809 | ENSG00000144381 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 3312 | HSPA8 | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 85389 | HSPA8 | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 85389 | SNORD14C | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 85390 | HSPA8 | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 85390 | SNORD14D | P11142 | ENSG00000109971 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 3301 | DNAJA1 | P31689 | ENSG00000086061 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 101927137 | ATP1A3 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 101927137 | CCT3 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 101927137 | FAM78A | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 101927137 | KIAA1456 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 101927137 | RN7SL784P | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 101927137 | SCLT1 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 7203 | CCT3 | P49368 | ENSG00000163468 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 60 | ACTB | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 60 | ACTG1 | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 10376 | TUBA1B | P68363 | ENSG00000123416 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 10381 | TUBB3 | Q13509 | ENSG00000258947 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 7846 | TUBA1A | Q71U36 | ENSG00000167552 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 84790 | TUBA1C | Q9BQE3 | ENSG00000167553 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 84617 | TUBB6 | Q9BUF5 | ENSG00000176014 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
Click here to search for all sets and networks involving any of the 9 genes of this set.
| Search | Entrez Gene ID | HGNC symbol | Associated diseases | HPO ID |
|---|---|---|---|---|
| Search | 2990 | GUSB | MUCOPOLYSACCHARIDOSIS TYPE VII (OMIM:253220 | HP:0002180 |
| Search | 5111 | PCNA | ATAXIA-TELANGIECTASIA-LIKE DISORDER 2 (OMIM:615919 | HP:0002180 |
| Search | 6531 | SLC6A3 | PARKINSONISM-DYSTONIA, INFANTILE (OMIM:613135 | HP:0001300 |
| Search | 5663 | PSEN1 | PICK DISEASE OF BRAIN (OMIM:172700, ACNE INVERSA, FAMILIAL, 3 (OMIM:613737, CARDIOMYOPATHY, DILATED, 1U (OMIM:613694, PRESENILIN 1 (OMIM:104311, FRONTOTEMPORAL DEMENTIA (OMIM:600274, ALZHEIMER DISEASE 3 (OMIM:607822 | HP:0001300 |
| Search | 4137 | MAPT | PICK DISEASE OF BRAIN (OMIM:172700, SUPRANUCLEAR PALSY, PROGRESSIVE, 1 (OMIM:601104, FRONTOTEMPORAL DEMENTIA (OMIM:600274, PARKINSON-DEMENTIA SYNDROMESUPRANUCLEAR ... (OMIM:260540 | HP:0001300 |
| Search | 5071 | PARK2 | PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE... (OMIM:600116, LUNG CANCERALVEOLAR CELL CARCINOMA, INCL... (OMIM:211980, OVARIAN CANCEROVARIAN CANCER, EPITHELIAL... (OMIM:167000 | HP:0001300 |
| Search | 348 | APOE | ALZHEIMER DISEASE 2 (OMIM:104310, LIPOPROTEIN GLOMERULOPATHY (OMIM:611771, APOLIPOPROTEIN E (OMIM:107741, SEA-BLUE HISTIOCYTE DISEASE (OMIM:269600 | HP:0001300 |
| Search | 6622 | SNCA | PARKINSON DISEASE 1, AUTOSOMAL DOMINANT (OMIM:168601, PARKINSON DISEASE 4, AUTOSOMAL DOMINANT ... (OMIM:605543, DEMENTIA, LEWY BODY (OMIM:127750 | HP:0001300 |
| Search | 351 | APP | CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED (OMIM:605714, ALZHEIMER DISEASE (OMIM:104300 | HP:0001300 |
| Search | 348 | APOE | ALZHEIMER DISEASE 2 (OMIM:104310, LIPOPROTEIN GLOMERULOPATHY (OMIM:611771, APOLIPOPROTEIN E (OMIM:107741, SEA-BLUE HISTIOCYTE DISEASE (OMIM:269600 | HP:0002511 |
| Search | 5663 | PSEN1 | PICK DISEASE OF BRAIN (OMIM:172700, ACNE INVERSA, FAMILIAL, 3 (OMIM:613737, CARDIOMYOPATHY, DILATED, 1U (OMIM:613694, PRESENILIN 1 (OMIM:104311, FRONTOTEMPORAL DEMENTIA (OMIM:600274, ALZHEIMER DISEASE 3 (OMIM:607822 | HP:0002511 |
| Search | 351 | APP | CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED (OMIM:605714, ALZHEIMER DISEASE (OMIM:104300 | HP:0002511 |
No gene from this dataset is present in any of the networks. You can explore the full highlight dataset by downloading the full data linked above.
Click here to search for all sets and networks involving any of the 1 genes of this set.
| Search | Entrez ID | HGNC Symbol | Ensembl Gene ID | Uniprot Accession | Reference | PMID |
|---|---|---|---|---|---|---|
| Search | 4137 | MAPT | ENSG00000186868 | P10636 | Simon-Sanchez et al. Nat Genet 2009 41:1308-1312 | 19915575 |
Click here to search for all sets and networks involving any of the 4 genes of this set.
| Search | Entrez ID | HGNC Symbol | Ensembl Gene ID | Uniprot Accession | Reference | PMID |
|---|---|---|---|---|---|---|
| Search | 6622 | SNCA | ENSG00000145335 | P37840 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 5071 | PARK2 | ENSG00000185345 | O60260 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 11315 | PARK7 | ENSG00000116288 | Q99497 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 120892 | LRRK2 | ENSG00000188906 | Q5S007 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |